Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMS CONSENT
We consent to the inclusion in this Registration Statement of Kintara Therapeutics, Inc. (the Company) on Amendment No. 2 to Form S-4 (File No. 333-279368) of our report dated September 18, 2023, which includes an explanatory paragraph as to the Companys ability to continue as a going concern, with respect to our audits of the consolidated financial statements of Kintara Therapeutics Inc, Inc. as of June 30, 2023 and June 30, 2022 and for the each of the two years in the period ended June 30, 2023, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading Experts in such Prospectus.
/s/ Marcum LLP
Marcum LLP
San Francisco, CA
July 19, 2024